科倫藥業(002422.SZ):控股股東提議以0.5億元-1億元回購股份
格隆匯 1 月 18日丨科倫藥業(002422.SZ)公佈,公司於2021年1月18日收到了公司控股股東劉革新《關於提議四川科倫藥業股份有限公司回購股份的函》。
劉革新基於對公司價值的高度認可和對公司未來發展前景的信心,考慮到公司股價的持續低迷,為增強投資者對公司的信心,確保公司發展戰略和經營目標的實現,特提議公司以自有資金通過集中競價交易方式進行股份回購。
結合近期公司股價,提議人劉革新提議回購價格上限不超過24元/股,回購總金額不低於5000萬元人民幣,不超過10000萬元人民幣。在回購股份價格不超過人民幣24元/股的條件下,按回購金額上限測算,預計回購股份數量約為416.67萬股,約佔公司當前總股本的0.2896%;按回購金額下限測算,預計回購股份數量約208.33萬股,約佔公司當前總股本的0.1448%。具體回購股份的金額以回購期限屆滿時實際回購的金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.